Home / Indicator library / Biotechnology and Medical Care / 6645 overview

6645 stock overview

Valuation, financials, growth, ownership, events, dividends, models and adjusted prices for this Taiwan-listed ticker, on one page

中文版 (Chinese)

6645 snapshot, key figures

Price / earnings

—

Price / book

1.77x

Dividend yield

—

Revenue YoY (2026-06)

43.9%

Monthly revenue (2026-06)

TWD 0.07bn

Sector

Biotechnology and Medical Care

Listing venue

Taiwan Stock Exchange

Values above are the official-source snapshot for 6645 on 2026-08-03. We do not chase live quotes. Every trading day is frozen as its own point-in-time vintage, so a backtest reading this data sees only what was actually knowable that day, with no look-ahead bias. Missing values stay blank. Nothing is interpolated or extrapolated.

6645: where today sits in the past year

Current value against the 2025-07-31 to 2026-07-31 range, built from 243 frozen daily vintages.

Price / book1.77x24th percentile of the past year

1.57xmedian 2.10x2.92x

The marker is today's value; the faint tick is the one-year median. Every point in this range is the number as it was published on its own date, never a restated figure, so the percentile is what a reader on that day could actually have computed. Ratios at or below zero are excluded rather than treated as cheap. Tickers with fewer than 60 observed dates get no range at all.

6645 reported 43.9% year-on-year monthly revenue growth for 2026-06, from the official monthly revenue filing.

Is 6645's price / book high or low right now?

6645's price / book is 1.77x, which is below its one-year median of 2.10x and sits at the 24th percentile of the 1.57–2.92x range observed over the last 243 snapshot dates. Each of those dates is a frozen point-in-time vintage, so the range contains no restated or back-filled values.

Other Biotechnology and Medical Care tickers

160 Taiwan-listed tickers sit in this sector. See the full Biotechnology and Medical Care table.

Everything on this page is either the official public source shown as-is, or a transparent derivation you can reproduce. The free tier covers 2330 in full as a reference case; on other tickers some blocks are paid-tier. What we sell is data and tooling, not investment advice, not stock tips, and not a promise of returns.